Merck & Co., Inc. (NYSE:MRK) Expected to Earn Q4 2025 Earnings of $2.39 Per Share

Merck & Co., Inc. (NYSE:MRK) – Stock analysts at Leerink Partnrs lifted their Q4 2025 earnings estimates for Merck & Co., Inc. in a research report issued on Saturday, April 20th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of $2.39 per share for the quarter, up from their prior estimate of $2.37. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $8.59 per share.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The business had revenue of $14.63 billion during the quarter, compared to analyst estimates of $14.49 billion. During the same period last year, the company earned $1.62 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 5.8% compared to the same quarter last year.

Several other analysts also recently commented on MRK. Truist Financial reissued a “buy” rating and issued a $142.00 target price (up from $139.00) on shares of Merck & Co., Inc. in a research report on Thursday, March 28th. Wells Fargo & Company increased their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 27th. Barclays boosted their price target on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Finally, Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $131.25.

Merck & Co., Inc. Trading Up 0.9 %

Shares of NYSE MRK opened at $126.94 on Tuesday. The business has a 50 day simple moving average of $126.21 and a 200 day simple moving average of $115.35. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10. The stock has a market cap of $321.54 billion, a price-to-earnings ratio of 906.71, a PEG ratio of 1.63 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25.

Insider Buying and Selling

In related news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the completion of the transaction, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Several institutional investors have recently added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $27,000. Bare Financial Services Inc acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $28,000. Burkett Financial Services LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth about $28,000. Rakuten Securities Inc. acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at about $30,000. Finally, RIA Advisory Group LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $30,000. 76.07% of the stock is owned by institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.